Shuang (George) Zhao, MD

The Zhao Lab focuses on developing novel clinical biomarkers that predict response and resistance to specific therapies across cancers. These biomarkers can be used to better select which patients derive a benefit from treatment, which patients do not and can be spared potential toxicity, as well as monitor for emergence of resistance. It seeks to use advanced computational approaches and liquid biopsy technologies to better personalize the care of cancer patients.

John Floberg, MD, PhD

Clinically, Dr. Floberg focuses on the treatment of genitourinary cancers. As a radiation oncologist, he collaborates with urologists, medical oncologists, radiologists, pathologists and other specialists to provide patients with the best care possible.

Pippa Cosper, MD, PhD

Dr. Cosper’s main interest is in Human Papilloma Virus (HPV) induced cancers, such as cervical and head and neck cancer. Specifically, she is interested in how the virus induces different types of chromosomal instability (CIN) and how this affects radiation sensitivity, which may offer some insight into radiation sensitivity or resistance within HPV+ cancers.

Grace Blitzer, MD

Dr. Blitzer is an assistant professor in the Department of Human Oncology at the University of Wisconsin. She serves as the primary radiation oncologist at the UW Cancer Center in Johnson Creek, where she treats all types of cancer in adults. The UW Cancer Center Johnson Creek has a state-of-the-art linear accelerator that is the same as the machines at UW Carbone Cancer Center, which allows me to treat cancer using the same advanced techniques available to UWCCC.

Peter Mahler, MD, PhD

In addition to general radiation oncology, Dr. Peter Mahler has a strong interest in palliative care. Approximately one half of all radiation oncology patients are treated with palliative intent. A significant fraction of those treated with curative intent develop recurrence months to years after their initial therapy and become palliative patients. Therefore, it is incumbent upon radiation oncologists to have well-honed palliative care skills in order to best serve their patients.

Steven Howard, MD, PhD

Dr. Steven Howard has expertise in the treatment of patients with brain tumors. His research focuses on the clinical application of new radiation techniques and radiation-drug combinations to improve outcomes for brain tumor patients. Dr. Howard has received numerous awards and honors for his work in Radiation Oncology.

Mark Ritter, MD, PhD

Dr. Ritter is a professor emeritus of Human Oncology and Medical Physics at the University of Wisconsin–Madison. Although he retired from active clinical service in 2018, he is still engaged in research, teaching and mentoring. My translational and clinical research focuses on genitourinary and gastrointestinal oncology. He has long-standing interests in the impact of tumor kinetics on tumor treatment response, exploring molecular and imaging biomarkers that predict or serve as surrogates for radiation response and investigating the impact of radiation hypofractionation on tumor response, particularly for prostate cancer.

Jessica Schuster, MD

Dr. Jessica Schuster ism a clinical associate professor in the Department of Human Oncology and serves as the primary radiation oncologist at UW Cancer Center Johnson Creek, where she treats all adult cancer sites. She has a particular interest in using radiation to treat breast, prostate and lung cancers and benign diseases such as Dupuytren’s contracture. She also focuses on palliative care and symptom management.

Kristin Bradley, MD

Dr. Bradley participates in clinical research, evaluating ways to improve cancer care in patients with gynecologic, hematologic or pediatric cancers who are receiving radiation as a component of their treatment. In addition to her clinical practice, she is the Radiation Oncology Residency Program director. She is also involved with teaching medical students and undergraduates.